Literature DB >> 8695853

Molecular characterization of antigenic polymorphisms (Ond(a) and Mart(a)) of the beta 2 family recognized by human leukocyte alloantisera.

S Simsek1, C E van der Schoot, M Daams, E Huiskes, M Clay, J McCullough, C van Dalen, D Stroncek, A E von dem Borne.   

Abstract

We show that the previously described alloantisera Ond and Mart, which recognize the alloantigens Ond(a) and Mart(a), react with polymorphic variants of alpha L and alpha M subunits of the beta 2 integrin family (CD11a and CD11b molecules). This was shown by testing the alloantisera in a monoclonal antibody-specific immobilization of leukocyte antigens, immunoprecipitation, and immunofluorescence assay against cells from normal donors and from patients with leukocyte adhesion deficiency (beta 2 intergrin deficient). To elucidate the molecular basis of the Ond(a) and Mart(a) alloantigens, RNA was isolated from mononuclear leukocytes derived from individuals of known serologic phenotype. Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to amplify the entire coding region of the alpha L and alpha M mRNAs. The Ond(a) antigen was found to be due to a G2466C substitution in the DNA coding for the alpha L subunit, which predicts an Arg766Thr amino-acid polymorphism. The Mart(a) antigen was also found to be due to a single nucleotide substitution (G302A) in the DNA coding for the alpha M subunit, which predicts an Arg61His amino acid polymorphism. Using allele-specific restriction enzyme analysis, the association between point mutations and phenotypes was confirmed. The localization of these alloantigens on integrin molecules further illustrates the polymorphic nature of this class of proteins. Whether the polymorphisms influence the adhesive capacity of the leukocyte integrins remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695853

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions.

Authors:  David F Stroncek; Emmanuel Fadeyi; Sharon Adams
Journal:  Transfus Med Rev       Date:  2007-10

Review 2.  Molecular nature of antigens implicated in immune neutropenias.

Authors:  Juergen Bux
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Is it time to reconsider neutrophil antibody testing of platelet donors?

Authors:  David F Stroncek; Mary Clay
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

4.  Granulocyte antibodies in Korean neonates with neutropenia.

Authors:  Tae Hee Han; Myoung-Jae Chey; Kyou Sup Han
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

5.  Human neutrophil alloantigen genotype frequencies in Thai blood donors.

Authors:  Khaimuk Changsri; Pussadee Tobunluepop; Dujdow Songthammawat; Teerakul Apornsuwan; Chollanot Kaset; Oytip Nathalang
Journal:  Blood Transfus       Date:  2013-01-23       Impact factor: 3.443

Review 6.  Molecular Genetics of the Human Neutrophil Antigens.

Authors:  Brigitte Katharina Flesch; Angelika Reil
Journal:  Transfus Med Hemother       Date:  2018-08-17       Impact factor: 3.747

7.  Genotyping of human neutrophil antigens (HNA) from whole genome sequencing data.

Authors:  Hsueh-Ting Chu; Han Lin; Theresa Tsun-Hui Tsao; Chun-Fan Chang; William Wl Hsiao; Tze-Jung Yeh; Ching-Mao Chang; Yen-Wenn Liu; Tse-Yi Wang; Ko-Chun Yang; Tsung-Jui Chen; Jen-Chih Chen; Kuang-Chi Chen; Cheng-Yan Kao
Journal:  BMC Med Genomics       Date:  2013-09-12       Impact factor: 3.063

8.  Heterogeneity of Human Neutrophil CD177 Expression Results from CD177P1 Pseudogene Conversion.

Authors:  Zuopeng Wu; Rong Liang; Thomas Ohnesorg; Vicky Cho; Wesley Lam; Walter P Abhayaratna; Paul A Gatenby; Chandima Perera; Yafei Zhang; Belinda Whittle; Andrew Sinclair; Christopher C Goodnow; Matthew Field; T Daniel Andrews; Matthew C Cook
Journal:  PLoS Genet       Date:  2016-05-26       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.